- Home
- NAUT vs SKYE Comparison
NAUT vs SKYE Comparison
Compare NAUT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- SKYE
- Stock Information
- Founded
- NAUT 2016
- SKYE 2012
- Country
- NAUT United States
- SKYE United States
- Employees
- NAUT N/A
- SKYE N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- SKYE Health Care
- Exchange
- NAUT Nasdaq
- SKYE Nasdaq
- Market Cap
- NAUT 104.7M
- SKYE 121.8M
- IPO Year
- NAUT N/A
- SKYE N/A
- Fundamental
- Price
- NAUT $0.90
- SKYE $1.71
- Analyst Decision
- NAUT Strong Sell
- SKYE Strong Buy
- Analyst Count
- NAUT 1
- SKYE 5
- Target Price
- NAUT $1.75
- SKYE $14.75
- AVG Volume (30 Days)
- NAUT 394.7K
- SKYE 1.5M
- Earning Date
- NAUT 10-28-2025
- SKYE 11-06-2025
- Dividend Yield
- NAUT N/A
- SKYE N/A
- EPS Growth
- NAUT N/A
- SKYE N/A
- EPS
- NAUT N/A
- SKYE N/A
- Revenue
- NAUT N/A
- SKYE N/A
- Revenue This Year
- NAUT N/A
- SKYE N/A
- Revenue Next Year
- NAUT N/A
- SKYE N/A
- P/E Ratio
- NAUT N/A
- SKYE N/A
- Revenue Growth
- NAUT N/A
- SKYE N/A
- 52 Week Low
- NAUT $0.62
- SKYE $1.14
- 52 Week High
- NAUT $3.03
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- NAUT 60.66
- SKYE 30.37
- Support Level
- NAUT $0.69
- SKYE $1.78
- Resistance Level
- NAUT $0.92
- SKYE $4.99
- Average True Range (ATR)
- NAUT 0.06
- SKYE 0.36
- MACD
- NAUT 0.01
- SKYE -0.19
- Stochastic Oscillator
- NAUT 70.67
- SKYE 0.78
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.